|1.||Feagan, Brian G: 9 articles (05/2015 - 08/2012)|
|2.||Parikh, Asit: 6 articles (09/2014 - 08/2012)|
|3.||Fox, Irving: 6 articles (09/2014 - 08/2012)|
|4.||Wyant, Tim: 6 articles (11/2013 - 09/2009)|
|5.||Sandborn, William J: 5 articles (11/2015 - 08/2013)|
|6.||Xu, Jing: 5 articles (09/2014 - 07/2013)|
|7.||Danese, Silvio: 4 articles (12/2015 - 08/2013)|
|8.||Colombel, Jean-Frédéric: 4 articles (10/2015 - 08/2013)|
|9.||Milch, Catherine: 4 articles (09/2014 - 08/2013)|
|10.||Peyrin-Biroulet, Laurent: 3 articles (07/2015 - 02/2014)|
03/01/2014 - "Vedolizumab, an α4β7 antibody, has completed phase 3 trials with very positive results especially for ulcerative colitis. "
02/01/2015 - "In phase III clinical trials, patients with ulcerative colitis had significantly higher rates of clinical response and clinical remission when treated with vedolizumab than when receiving placebo at both 6 and 52 weeks. "
01/01/2014 - "Moderate to high quality data from four studies shows that vedolizumab is superior to placebo for induction of clinical remission and response and endoscopic remission in patients with moderate to severely active ulcerative colitis and prevention of relapse in patients with quiescent ulcerative colitis. "
01/01/2014 - "Moderate quality data from one study suggests that vedolizumab is superior to placebo for prevention of relapse in patients with quiescent ulcerative colitis. "
11/01/2010 - "Data from phase II clinical trials of vedolizumab demonstrated efficacy with an attractive safety profile, especially in ulcerative colitis. "
|2.||Crohn Disease (Crohn's Disease)
02/01/2015 - "In the Crohn's disease study that included maintenance treatment, vedolizumab was significantly more effective at 52 weeks than placebo in both endpoints (clinical remission was the only primary endpoint in the maintenance study). "
08/22/2013 - "Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolizumab (rather than switching to placebo) were more likely to be in remission at week 52. "
08/22/2013 - "At week 6, a total of 14.5% of the patients in cohort 1 who received vedolizumab and 6.8% who received placebo were in clinical remission (i.e., had a score on the Crohn's Disease Activity Index [CDAI] of ≤150, with scores ranging from 0 to approximately 600 and higher scores indicating greater disease activity) (P=0.02); a total of 31.4% and 25.7% of the patients, respectively, had a CDAI-100 response (≥100-point decrease in the CDAI score) (P=0.23). "
08/22/2013 - "The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown. "
08/22/2013 - "In an integrated study with separate induction and maintenance trials, we assessed intravenous vedolizumab therapy (300 mg) in adults with active Crohn's disease. "
|3.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
07/01/2015 - "As higher therapeutic mAb concentrations have been associated with greater efficacy in inflammatory bowel disease, understanding determinants of vedolizumab clearance may help to optimise dosing. "
12/01/2013 - "A new gut-specific monoclonal antibody, vedolizumab, has been shown to be effective in inflammatory bowel disease, and in continued trials no patients have developed PML. "
10/01/2013 - "Finally, several studies were presented on new drugs with new therapeutic targets, such as vedolizumab, in the treatment of inflammatory bowel disease. "
07/01/2015 - "Vedolizumab is a novel, gut-specific, anti-integrin agent used for the treatment of inflammatory bowel disease (IBD). "
04/01/2015 - "Vedolizumab (VDZ), a humanized monoclonal antibody that selectively targets α4β7 integrin, is approved for use in inflammatory bowel disease (IBD). "
|4.||Progressive Multifocal Leukoencephalopathy
09/01/2015 - "Since vedolizumab is gastrointestinal selective, to date, it has not shown evidence of causing progressive multifocal leukoencephalopathy; however, postmarketing studies monitoring for this adverse effect are ongoing. "
12/01/2014 - "Vedolizumab is generally well tolerated and has not been associated with progressive multifocal leukoencephalopathy."
04/01/2014 - "The drug is well tolerated and there have been no deaths or reports of progressive multifocal leukoencephalopathy infection in patients receiving vedolizumab. "
02/01/2015 - "As vedolizumab is a specific α4β7 integrin antagonist, with gut-specific effects, it is unlikely to be associated with the development of progressive multifocal leukoencephalopathy, a risk observed with the less selective α4β7/α4β1 integrin antagonist natalizumab. "
01/01/2014 - "The safety profile of vedolizumab appears reasonable, possibly because it has a "gut-selective" mode of action, with no reported cases of progressive multifocal leukoencephalopathy, a condition which has been linked to another integrin antagonist, natalizumab. "
|5.||Body Weight (Weight, Body)
|9.||Immunologic Factors (Immunomodulators)